Use of fondaparinux as an anticoagulant during hemodialysis: A preliminary study

International Journal of Clinical Pharmacology and Therapeutics

Volumn 46, Issue 4, 2008, Pages 198-203

  Sombolos, K I ^a,c   Fragia, T K ^b   Gionanlis, L C ^a   Veneti, P E ^a   Bamichas, G I ^a   Fragidis, S K ^a   Georgoulis, I E ^b   Natse, T A ^a  

^a Renal Unit   (Greece)

^b Hematology Laboratory   (Greece)

^c NONE   (Greece)

Author keywords

Arixtra; Fondaparinux; Hemodialysis; High flux

Indexed keywords

BICARBONATE; BLOOD CLOTTING FACTOR 10A; FIBRIN; FONDAPARINUX; HEPARIN; POLYESTER; POLYSULFONE; SODIUM CHLORIDE; THROMBOPLASTIN; TINZAPARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; ARTIFICIAL KIDNEY; BLOOD CLOTTING; BLOOD SAMPLING; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG DISTRIBUTION; DRUG HALF LIFE; EXTRACORPOREAL CIRCULATION; FEMALE; HEMODIALYSIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; MALE; NEPHROSCLEROSIS; PARTIAL THROMBOPLASTIN TIME; THROMBOSIS; TIME; TREATMENT OUTCOME;

EID: 41849105427     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP46198     Document Type: Article

References (17)

1. Amanzadeh J, Reilly R. Anticoagulation and Continuous renal replacement therapy. Semin Dial. 2006; 19. 311-316.
2. Bauer K. New anticoagulants. Hematol Am Soc Hematol Educ Prog. 2006; p. 450-456.
3. Christidou FN, Frangia TK, Bamichas GI, Gionanlis LC, Natse TA, Georgoulis IE, Sombolos KI. Comparison of two low-molecular weight heparins (LMWHs), tinzaparin and bemiparin, during hemodialysis. Int J Clin Pharmacol Ther. 2005; 43: 335-338.
4. Daugirdas JT. Second-generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol. 1993; 4: 1205-1213.
5. Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review. Semin Thromb Hemost. 2006; 32: 803-809.
6. Grau E, Siguenza F, Maduell F, Linares M, Olaso MA, Martinez R, Caridad A. Low-molecular weight heparin (CY-216) versus unfractionated heparin in chronic hemodialysis. Nephron. 1992; 62: 13-17.
7. Guillet B, Simon N, Sampol JJ, Lorec-Penet AM, Portugal H, Berland Y, Dussol B, Brunet P. Pharmacokinetics of the low-molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. Nephrol Dial Transplant. 2003; 18: 2348-2353.
8. Haase M, Bellomo R, Rocktaeschel J, Ziemer S. Kiesewetter H, Morgera S, Neumayer HH. Use of fondaparinux (ARIXTRA®) in a dialysis patient with symptomatic heparin-induced thrombocytopaenia Type II. Nephrol Dial Transplant. 2005; 20: 444-446.
9. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001; 119 (1 Suppl): 64S-94S.
10. Internet. www.arixtra.com. 2006.
11. Isla A, Gascon AR, Maynar J, Arzuaga A, Corral E, Martin A, Solinis MA, Munoz JL. In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes. Clin Ther. 2005; 27: 1444-1451.
12. Lai KN, Wang AYM, Ho K, Szeto CC, Wong LKS, Yu AWY. Use of low-molecular weight heparin in hemodialysis. Am J Kidney Dis. 1996; 28: 721-726.
13. Matata BM, Courtney JM, Sundaram S, Wark S, Bowry SK, Vienken J, Lowe GD. Determination of contact phase activation by the measurement of the activity of supernatant and membrane surface-adsorbed factor XII (FXII): its relevance as a useful parameter for the in vitro assessment of haemodialysis membranes. J Biomed Mater Res. 1996; 31: 63-70.
14. McMahon LP, Chester K, Walker RG. Effects of different dialysis membranes on serum concentrations of epoetin-alfa, darbepoetin-alfa, enoxaparin, and iron sucrose during dialysis. Am J Kidney Dis. 2004; 44: 509-516.
15. Reynolds NA, Perry CM, Scott LJ. Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery. Drugs. 2004; 64: 1575-1596.
16. Sharathkumar AA, Crandall C, Lin JJ, Pipe S. Treatment of thrombosis with fondaparinux (Arixtra) in a patient with end-stage renal disease receiving hemodialysis therapy. J Pediatr Hematol Oncol. 2007; 29: 581-584.
17. Warkentin T, Mauer B, Aster R. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med. 2007; 356: 2653-2655.